Bioinformatic Analysis of B- and T-cell Epitopes from SARS-CoV-2 Structural Proteins and their Potential Cross-reactivity with Emerging Variants and other Human Coronaviruses-Reference-Cited by-同舟云学术

Bioinformatic Analysis of B- and T-cell Epitopes from SARS-CoV-2 Structural Proteins and their Potential Cross-reactivity with Emerging Variants and other Human Coronaviruses

Published:2022-11 Issue:7 Volume:53 Page:694-710
ISSN:0188-4409
Container-title:Archives of Medical Research
language:en
Short-container-title:Archives of Medical Research

Author:

Pacheco-Olvera Diana Laura,Saint Remy-Hernández Stephanie^ORCID,García-Valeriano María Guadalupe,Rivera-Hernández Tania,López-Macías Constantino^ORCID

Funder

Sistema Nacional de Investigadores

Consejo Nacional de Ciencia y Tecnología

Publisher

Elsevier BV

Subject

General Medicine

Reference124 articles.

1. Structural biology of SARS-CoV-2 and implications for therapeutic development;Yang;Nat Rev Microbiol,2021

2. ArcGIS Dashboards 2020. Available from: https://www.arcgis.com/apps/dashboards/bda7594740fd40299423467b48e9ecf6. (Accessed November 22, 2021).

3. An interactive web-based dashboard to track COVID-19 in real time;Dong;Lancet Infect Dis,2020

4. SARS-CoV-2 vaccine effectiveness against infection, symptomatic and severe COVID-19: a systematic review and meta-analysis;Ssentongo;BMC Infect Dis,2022

5. Farmacovigilancia de vacunas para COVID-19 - Catálogo. Farmacovigilancia de vacunas para COVID-19 2022. Available from: https://covid-19pharmacovigilance.paho.org/(Accessed August 10, 2022).

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Newcastle disease virus vector-based SARS-CoV-2 vaccine candidate AVX/COVID-12 activates T cells and is recognized by antibodies from COVID-19 patients and vaccinated individuals;Frontiers in Immunology;2024-05-30

2. Newcastle Disease Virus Vector-Based SARS-CoV-2 Vaccine Candidate AVX/COVID-12 Activates T Cells and Is Recognized by Antibodies from COVID-19 Patients and Vaccinated;2024-03-04

3. Phase II/III Double-Blind Study Evaluating Safety and Immunogenicity of a Single Intramuscular Booster Dose of the Recombinant SARS-CoV-2 Vaccine “Patria” (AVX/COVID-12) Using an Active Newcastle Disease Viral Vector (NDV) during the Omicron Outbreak in Healthy Adults with Elevated Baseline Antibody Titers from Prior COVID-19 and/or SARS-CoV-2 Vaccination;2024-02-14

4. Однократная интраназальная иммунизация высокой дозой гриппозного вектора вызывает защитный эффект при заражении гетерологичным вирусом гриппа и SARS-CoV-2 у хорьков и хомяков;Microbiology Independent Research Journal (MIR Journal);2024

5. Single intranasal immunization with a high dose of influenza vector protects against infection with heterologous influenza virus and SARS-CoV-2 in ferrets and hamsters;Microbiology Independent Research Journal (MIR Journal);2024